Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes

Pharmaceutical Research

Volumn 16, Issue 8, 1999, Pages 1309-1315

  Yu, Rosie Z ^a   Geary, Richard S ^a   Leeds, Janet M ^a   Watanabe, Tanya ^a   Fitchett, Jonathon R ^a   Matson, John E ^a   Mehta, Rahul ^a   Hardee, Gregory R ^a   Templin, Michael V ^a   Huang, Ken ^b   Newman, Mary S ^b   Quinn, Yoli ^b   Uster, Paul ^b   Zhu, George ^b   Working, Peter K ^b   Horner, Michelle ^c   Nelson, Joyce ^c   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b ALZA CORPORATION   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antisense phosphorothioate oligonucleotide; Capillary gel electrophoresis; Monkey; Pharmacokinetics; Stealth liposome

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 2503; LIPOSOME; NUCLEASE; PHOSPHATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG TISSUE LEVEL; ENCAPSULATION; FEMALE; GEL ELECTROPHORESIS; MALE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; RHESUS MONKEY;

ANIMALS; BLOOD PROTEINS; CAPSULES; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION; HALF-LIFE; KINETICS; LIPOSOMES; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; OLIGONUCLEOTIDES, ANTISENSE; RAS PROTEINS; TISSUE DISTRIBUTION;

EID: 0032872495     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014822219133     Document Type: Article

References (30)

1. 1. B. P. Monia, J. F. Johnston, D. J. Ecker, M. Zounes, W. F. Lima, and S. M. Freier. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 19954-19962 (1992).
2. 2. C. F. Bennett, N. Dean, D. J. Ecker, and B. P. Monia. Pharmacology of antisense therapeutic agents. In S. Agrawal (ed.), Methods in Molecular Medicine: Antisense Therapeutics, Humana Press Inc., Totowa, NJ, 1996, pp. 13-46.
3. 3. L. M. Cowsert. In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Anti-Cancer Drug Des. 12:359-371 (1997).
4. 4. P. A. Cossum, L. Troung, S. R. Owens, P. M. Markham, J. P. Shea, and S. T. Crooke. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 1:89-94 (1994).
5. 5. P. A. Cossum, H. Sasmor, D. Dellinger, L. Troung, L. Cummins, S. R. Owens, P. M. Markham, J. P. Shea, and S. Crooke. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 3:1181-1190 (1993).
6. 6. R. S. Geary, J. M. Leeds, J. Fitchett, T. Burckin, L. Troung, C. Spainhour, M. Creek, and A. A. Levin. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25:1272-1281 (1997).
7. 7. S. Agrawal, J. Temsamani, W. Galbraith and J. Tang. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28:7-16 (1995).
8. 8. R. Zhang, J. Van, H. Shahinian, G. Amin, Z. Lu, T. Liu, M. S. Saag, Z. Jiang, J. Temsamani, R. Martin, P. J. Schechter, S. Agrawal, and R. B. Diasio. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58:45-53 (1995).
9. 9. E. Bayever, P. L. Iversen, M. R. Bishop, J. G. Sharp, H. K. Tewary, M. A. Arneson, S. J. Pirruccello, R. W. Ruddon, A. Kessinger, G. Zon, and J. O. Armitage. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic syndrome: initial results of a phase 1 trial. Antisense Res. Dev. 3:383-390 (1993).
10. 10. J. M. Glover, J. M. Leeds, T. G. Mant, D. Amin, D. L. Kisner, J. E. Zuckerman, R. S. Geary, A. A. Levin, and W. R. Shanahan. Phase 1 safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282:1173-1180 (1997).
11. 11. R. S. Geary, J. M. Leeds, S. P. Henry, D. K. Monteith, and A. A. Levin. Antisense oligonucleotide inhibitors for treatment of cancer: I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12:383-393 (1997).
12. 12. S. Agrawal, J. Temsamani, and J. Y. Tang. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U. S. A. 88:7595-7599 (1991).
13. 13. L. Iversen, J. Mata, W. G. Tracewell, and G. Zon. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4:43-52 (1994).
14. 14. D. C. Litzinger, J. M. Brown, I. Wala, S. A. Kaufman, G. Y. Van, C. L. Farrell, and D. Collins. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta. 1281:139-149 (1996).
15. 15. D. D. Ma and A. Q. Wei. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk. Res. 20:925-930 (1996).
16. 16. O. Zelphati, J. L. Imbach, N. Signoret, G. Zon, B. Rayner, and L. Leserman. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22:4307-4314 (1994).
17. 17. F. Yuan, M. Leunig, S. K. Huang, D. A. Berk, D. Papahadjopoulos, and R. K. Jain. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:3352-6 (1994).
18. 18. P. K. Working and A. D. Dayan. CAELYX: Pharmacological-toxicological expert report. Hum. Exp. Toxicol. 15:751-85 (1996).
19. 19. A. Gabizon and F. Martin. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 54 Suppl. 4:15-21 (1997).
20. 20. M. Grunaug, J. R. Bogner, O. Loch, and F. D. Goebel. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. Eur. J. Med. Res. 3:13-9 (1998).
21. 21. M. S. Newman, G. T. Colbern, P. K. Working, C. Engbers, and M. A. Amantea. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor bearing mice. Cancer Chemther. Pharmacol. 43:1-7 (1999).
22. 22. L. Beaucage and R. P. lyer. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron. 48:2223-2311 (1992).
23. 23. S. P. Henry, P. C. Giclas, J. M. Leeds, M. Pangburn, C. Auletta, A. A. Levin, and D. J. Kornbrust. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. 281:810-816 (1997).
24. 24. J. M. Leeds, M. J. Graham, L. Truong and L. L. Cummins. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235:36-43 (1996).
25. 25. R. H. Griffey, M. J. Greig, H. J. Gaus, K. Liu, D. K. Monteith, M. Winniman, and L. L. Cummins. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer. J. Mass. Spectrom. 32:305-313 (1997).
26. 26. J. C. Bigelow, L. R. Chirin, L. A. Mathews, and J. J. McCormack. High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J. Chromatogr. Biomed. Appl. 133-140 (1990).
27. 27. S. Agrawal, X. Zhang, Q. Cai, E. R. Kandimalla, A. Manning, Z. Jiang, T. Marcel, and R. Zhang. Effect of asprin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats. J. Drug Target. 5:303-312 (1998).
28. 28. B. Davies and T. Morris. Physiological Parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
29. 29. H. J. Gaus, S. R. Owens, M. Winniman, S. Cooper, and L. L. Cummins. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal. Chem. 69:313-319 (1997).
30. 30. J. Rappaport, B. Hanss, J. B. Kopp, T. D. Copeland, L. A. Bruggeman, T M. Coffman, and P. E. Klotman. Transport of phosphorothioate oligonucleotide in kidney: Implications for molecular therapy. Kidney Int. 47:1462-1469 (1995).